공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

시토크롬 P450 11B2 미토콘드리아 : 파이프라인 리뷰

Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 359842
페이지 정보 영문 42 Pages
가격
US $ 3,500 ₩ 3,904,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,809,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,714,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


시토크롬 P450 11B2 미토콘드리아 : 파이프라인 리뷰 Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 42 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

시토크롬 P450 11B2 미토콘드리아(Cytochrome P450 11B2 Mitochondrial)를 표적으로 하는 약제의 적응증, 개발 단계, 작용기서, 투여 경로 및 분자 종류별 분석, 약제의 약리 작용에 관한 설명, 지금까지의 연구 개발 동향, 최신 뉴스와 발표, 약제 개발에 참여하고 있는 주요 기업 개요, 휴지/중지된 프로젝트 정보 등을 전해드립니다.

서론

  • 조사 범위

시토크롬 P450 11B2 미토콘드리아 개요

치료제 개발

시토크롬 P450 11B2 미토콘드리아 : 개발중인 제품 - 개발 단계별

시토크롬 P450 11B2 미토콘드리아 : 개발중인 제품 - 치료 범위별

시토크롬 P450 11B2 미토콘드리아 : 개발중인 제품 - 적응증별

시토크롬 P450 11B2 미토콘드리아 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

시토크롬 P450 11B2 미토콘드리아 : 기업에서 개발중인 제품

시토크롬 P450 11B2 미토콘드리아 : 대학/기관에서 개발중인 제품

시토크롬 P450 11B2 미토콘드리아 : 치료제 평가

  • 단독요법/병용 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

시토크롬 P450 11B2 미토콘드리아 치료제 개발에 참여하고 있는 기업

  • Angion Biomedica Corp.
  • Merck & Co., Inc.
  • Novartis AG

약제 개요

시토크롬 P450 11B2 미토콘드리아 : 휴지중인 프로젝트

시토크롬 P450 11B2 미토콘드리아 : 개발이 중지된 제품

부록

KSM 16.06.27

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Angion Biomedica Corp, H2 2019
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pipeline by CinCor Pharma Inc, H2 2019
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Pipeline by Damian Pharma AG, H2 2019
  • Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Recordati SpA, H2 2019
  • Pipeline by Selenity Therapeutics Inc, H2 2019
  • Pipeline by Target Medicals LLC, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019

Summary

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Aldosterone synthase is a steroid hydroxylase cytochrome P450 enzyme involved in the biosynthesis of the mineralocorticoid aldosterone. It is only expressed in the zona glomerulosa of the adrenal cortex and is primarily regulated by the renin-angiotensin system. It synthesizes aldosterone in humans and plays an important role in electrolyte balance and blood pressure. Inhibition of aldosterone synthase is used as a medical treatment for hypertension, heart failure, and renal disorders.

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hormonal Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders and Oncology which include indications Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Hyperaldosteronism, Resistant Hypertension, Cardiometabolic Disease, Cardiovascular Disease, Cushing's Syndrome, Endocrine Gland Disorders, Hypertension, Kidney Fibrosis, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myocardial Fibrosis, Pituitary ACTH Hypersecretion (Cushing Disease), Polycystic Kidney Disease and Primary Hyperaldosteronism.

The latest report Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019, outlays comprehensive information on the Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
  • The report reviews Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Overview
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Companies Involved in Therapeutics Development
  • Angion Biomedica Corp
  • Boehringer Ingelheim International GmbH
  • CinCor Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Damian Pharma AG
  • Laekna Therapeutics Shanghai Co Ltd
  • Merck & Co Inc
  • Recordati SpA
  • Selenity Therapeutics Inc
  • Target Medicals LLC
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Drug Profiles
  • ANG-3586 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BI-689648 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CIN-107 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DP-13 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LAE-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osilodrostat phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SE-6440 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CYP11B2 for Cardiovascular Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CYP11B2 for Chronic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CYP11B2 for Resistant Hypertension - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Dormant Products
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Discontinued Products
  • Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 15, 2019: CHMP adopts positive opinion for Isturisa
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q